Intradermal immunoengineering with mRNA

Area of Science:

• Biomedical Engineering
• Dermatology
• Immunology

Background:

• Intradermal (ID) delivery of mRNA therapeutics offers advantages like self-administration and direct immune cell access.
• Current ID nucleic acid delivery is validated for vaccines and tissue regeneration but limited for non-inflammatory applications due to barriers.

Purpose of the Study:

• To review the physicochemical and immunological barriers hindering broader ID mRNA therapeutic applications.
• To propose strategies for ID immunoengineering to overcome these barriers.

Main Methods:

• Examination of nanoparticle interactions with dermal components (lymphovascular network, collagen, glycosaminoglycans).
• Analysis of the dermal immunological landscape, including innate sensing by skin cells (macrophages, dendritic cells, fibroblasts).
• Discussion of how nanomaterial chemistry influences immune responses.

Main Results:

• Physicochemical challenges involve nanoparticle interactions within the complex dermal microenvironment.
• Immunological barriers stem from cell-type-specific innate sensing and nanomaterial-induced immune responses.
• Understanding the nanomaterial-biological interface is crucial for ID immunoengineering.

Conclusions:

• Mechanistic investigation of ID mRNA delivery in human skin models is needed.
• Selective engagement of the innate immune system can transform the dermis into an accessible platform for nucleic acid medicine.
• Overcoming ID barriers will expand mRNA therapeutics to protein replacement, tolerogenic vaccines, and local antibody production.